Contraindicated (one)bortezomib will boost the stage or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or reasonable CYP2C19 inhibitors may perhaps improve mavacamten systemic exposure, resulting in coronary heart failure because of systolic dysfunction. Lab and/or clinical tests (including total blood rely) should be performed while you https://zanecxnhu.isblog.net/detailed-notes-on-dup-747-43851718